$Vir Biotechnology, Inc.(VIR)$

Glaxo Antibody Treatment Works on Omicron Mutations in Study

7 December 2021

GlaxoSmithKline Plc said research shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new omicron variant.

Tests done in-vitro against a pseudo-virus that recreates a synthesized version of omicron showed that sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the omicron variant and not just the key mutations, the drugmaker said in a statement Tuesday. The tests included all 37 mutations identified to-date in the spike protein.

Does this mean VIR will spike now?

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论3

  • 推荐
  • 最新
  • FabianGracie
    ·2021-12-08
    这个科维克斯家族非常聪明,就像每一代毒液都变得更具破坏性一样。
    回复
    举报
  • Tracccy
    ·2021-12-08
    I believe the vaccine of the future can defeat this virus completely! I don't like wearing masks!🤧
    回复
    举报
  • JulianAlerander
    ·2021-12-08
    我只能说,今天的医疗公司是有准备的,不像过去那样毫无准备
    回复
    举报